Squamous cell carcinoma antigen-IgM is associated with hepatocellular carcinoma in patients with cirrhosis: A prospective study
| Autor: | Mariagrazia Ruvoletto, Andrea Gallotta, A. Martini, Patrizia Pontisso, Paolo Angeli, E. Trotta, Angelo Gatta, Silvano Fasolato, Alessandra Biasiolo, Giorgio Fassina |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Liver Cirrhosis Male Pathology medicine.medical_specialty Carcinoma Hepatocellular Cirrhosis Hepatocellular carcinoma Physical examination Gastroenterology Cohort Studies Biomarker Circulating immunocomplexes Hepatology 03 medical and health sciences 0302 clinical medicine Antigens Neoplasm Liver Cirrhosis Alcoholic Internal medicine Biomarkers Tumor Humans Medicine Decompensation Prospective Studies Prospective cohort study Serpins Aged medicine.diagnostic_test business.industry Liver Neoplasms Retrospective cohort study Hepatitis C Hepatitis C Chronic Middle Aged Prognosis medicine.disease digestive system diseases Immunoglobulin M 030220 oncology & carcinogenesis Biomarker (medicine) Female 030211 gastroenterology & hepatology alpha-Fetoproteins business Follow-Up Studies |
| Zdroj: | Digestive and Liver Disease. 48:197-202 |
| ISSN: | 1590-8658 |
| DOI: | 10.1016/j.dld.2015.10.022 |
| Popis: | Background Squamous cell carcinoma antigen (SCCA)-IgM complex has been described as a promising tool to identify patients with progressive liver disease at higher risk of hepatocellular carcinoma (HCC) development in retrospective studies. Aim To assess the clinical value of this biomarker in patients with cirrhosis in a prospective study. Methods Patients with overt cirrhosis were prospectively evaluated at 6-month intervals for HCC development and decompensation with clinical examination, liver ultrasound, α-fetoprotein measurement. SCCA-IgM was measured in serum by immunoenzymatic assay. Median follow-up duration was 52 months (range 12–68 months). Results 70 patients (26% male; mean age 56 ± 10 years) were enrolled. The main aetiological factors were alcohol (44%) and hepatitis C (34%). Baseline values of SCCA-IgM were significantly higher in patients who developed HCC. Positivity of the biomarker at baseline was associated with a significantly shorter HCC-free survival, while α-fetoprotein (cut off >20 ng/ml) was not significant. SCCA-IgM positivity and hepatitis C were significant prognostic factors for HCC development. The biomarker was not associated with the development of clinical complications of cirrhosis. Conclusion This prospective study demonstrates that in patients with cirrhosis SCCA-IgM is associated with HCC development and may be useful for clinical management of cirrhotic patients at higher risk of HCC development. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect